MTOR and ganglioneuroma: As the patient experienced significant urinary and bowel symptoms prior to the availability of genetic confirmation for NF-1, the patient was first started on a mammalian target of rapamycin (mTOR) inhibitor sirolimus, based on in vitro studies suggesting treatment response of ganglioneuroma to mTOR inhibitor (11).